Encouraging Phase 2 data on cenerimod – Idorsia’s S1P1 receptor modulator currently investigated for SLE – presented at ACR 2019

by NASDAQ Market News November 11, 2019

NASDAQ Market News
Click here to email author

Roche’s Gazyva (obinutuzumab), in combination with standard of care, more than doubles the percentage of lupus nephritis patients achieving complete renal response, compared to standard of care alone

NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

Ads